Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIMBLE: Pozelimab + Cemdisiran vs Cemdisiran in Generalized Myasthenia Gravis
jRCT2071220059Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Randomised, double-blind trial of pozelimab and cemdisiran in myasthenia gravis (MG) (4 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Change in Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score. Started Dec 2022; status: recruiting.
02
Drugs
pozelimabcemdisiran
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on jRCT2071220059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220059.